68 studies found for:    Trastuzumab emtansine (T–DM1)
Show Display Options
Rank Status Study
1 Completed
Has Results
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Trastuzumab emtansine
2 Active, not recruiting A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Condition: HER2 Positive Breast Cancers
Interventions: Drug: ONT-380;   Drug: T-DM1
3 Active, not recruiting A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Condition: Breast Cancer
Interventions: Drug: T-DM1;   Drug: Trastuzumab
4 Recruiting T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Condition: Breast Cancer
Interventions: Drug: Trastuzumab;   Drug: Paclitaxel;   Drug: Trastuzumab emtansine
5 Completed
Has Results
A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Trastuzumab emtansine [Kadcyla]
6 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: Trastuzumab emtansine [Kadcyla]
7 Recruiting A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Neratinib;   Drug: T-DM1
8 Completed
Has Results
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Condition: Metastatic Breast Cancer
Interventions: Biological: pertuzumab;   Biological: Trastuzumab emtansine [Kadcyla]
9 Active, not recruiting A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: trastuzumab emtansine
10 Recruiting A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
Condition: Breast Cancer
Intervention: Drug: Trastuzumab Emtansine
11 Completed
Has Results
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab
Condition: Metastatic Breast Cancer
Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg;   Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg;   Drug: Pertuzumab 420 mg
12 Completed
Has Results
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine;   Drug: Treatment of physician's choice
13 Withdrawn Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Trastuzumab emtansine
14 Recruiting T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Conditions: HER-2 Positive Breast Cancer;   Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Drug: T-DM1;   Drug: Pertuzumab;   Procedure: Excision of tumor/mastectomy
15 Recruiting Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
Condition: Advanced Breast Cancer
Intervention: Drug: PD-0332991 and T-DM1
16 Not yet recruiting Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
Conditions: Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: Vinorelbine;   Drug: Trastuzumab Emtansine
17 Recruiting A Phase II Study to Evaluate the Efficacy, and Safety of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) or Pancreas/Cholangio Cancer (Kameleon Study)
Condition: Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
Intervention: Drug: Trastuzumab Emtansine
18 Active, not recruiting A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
Condition: Solid Tumors
Interventions: Drug: Capecitabine;   Drug: Trastuzumab emtansine
19 Completed
Has Results
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: Taxane;   Drug: trastuzumab emtansine
20 Active, not recruiting BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BYL719;   Biological: ado-trastuzumab emtansine;   Other: pharmacological study;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.